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Abstract
Objective: The aim was to review and update advances in genetics of obesity.
Design: Analysis and interpretation of recent investigations about regulating the
energy balance as well as about gene-nutrient interactions and current nutri-
genomic research methods.
Background and main statements: Obesity results from a long-term positive
energy balance. However, its rising prevalence in developed and developing
societies must reflect lifestyle changes, since genetic susceptibility remains stable
over many generations. Like most complex diseases, obesity derives from a failure
of adequate homoeostasis within the physiological system controlling body
weight. The identification of genes that are involved in syndromic, monogenic
and polygenic obesity has seriously improved our knowledge of body weight
regulation. This disorder may arise from a deregulation at the genetic level
(e.g. gene transcription or altered protein function) or environmental exposure
(e.g. diet, physical activity, etc.).
Conclusions: In practice, obesity involves the interaction between genetic and
environmental factors.
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While it is clear that environmental factors play a sig-
nificant role in the development of obesity, research work
over the last decades has clearly documented a genetic
contribution to obesity-related phenotypes as well.
Obesity and its related traits represent the archetype of
a common complex phenotype. The configuration of
multiple genes can range from polygenic (i.e. many genes
with a relatively small contribution) to oligogenic (i.e. few
genes with large measurable effects often expressed on a
residual polygenic background)1. Indeed, it is this oligo-
genic architecture that justified all current efforts to map
genes for complex phenotypes.
Prior to the mid-1990s, most of the work on genetics of
human obesity had been limited to demonstrating that
variation in a wide range of obesity-related phenotypes
could be attributable to varying degrees to the effects of
genes2. Quantitative genetics analyses (twins, siblings and
family studies) have shown significant heritability, indi-
vidual’s chances of being obese are increased when
having obese relatives, with estimates of heritability
generally ranging from 30% to 70%. Different sets of
monozygotic twins overfed showed differences in the
degree to which excess calories were stores of fat, but the
tendency towards increased adiposity within each set of
twins were very similar, indicating that genetic factors
play a major role in the individual susceptibility to gain
weight in a specific environment3–5.
From the late 1980s through the early 1990s, segrega-
tion analysis was utilised in an effort to dissect further the
genetic component underlying human obesity by
attempting to detect the effects of anonymous major
genes on obesity-related phenotypes. A number of these
studies have reported consistent evidence of an anon-
ymous major gene effect accounting for as much as 40%
of the variation in body mass index (BMI) or fat mass in a
variety of populations2.
By the early to mid-1990s, researchers began to focus
on the goal of identifying the specific genes involved.
Initially, such efforts to identify specific genes influencing
complex traits such as those associated to obesity relied
on the use of a priori selected candidates genes. Such
candidates genes are selected on the basis of their per-
ceived role or function in biochemical pathways relevant
to the specific phenotype of interest (e.g. the structural
gene for a circulating protein). The conservation of
hypothalamic pathways in rodents and humans has cer-
tainly aided in choosing suitable candidates genes. All the
spontaneously occurring obesity mutations in mice either
have been found to harbour functionally relevant muta-
tions in humans too or have led to the identification of
a system/pathway in which other genes were found to
be mutated. The tools recently developed allow easy
determination of most gene polymorphisms from a
blood sample, especially single-nucleotide polymorphism
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(SNP). This advancement opens a new era where
research work devoted to study the interaction among
diets, metabolic variables, disease risk factors and gene
polymorphism can be carried out. According to the last
available version of the Gene Obesity Map (2004) there
are more than 600 genes, markers and chromosomal
regions involved in body weight regulation and obesity
development6.
Genetics of body weight regulation
Body weight regulation and stability depends upon an
axis with three interrelated components: food intake,
energy expenditure and adipogenesis, although there are
still many unknown features concerning fuel homo-
eostasis and energy balance. There are 358 studies on
obese humans reporting positive associations with 113
candidate genes. Among them, 18 genes are supported by
at least five positive studies6 (Fig. 1). Here we will sum-
marise a number of mutations in genes encoding factors
regulating food/energy intake and factors implicated in
energy expenditure and adiposity.
Genes encoding factors regulating food/energy
intake
It was generally accepted that hypothalamic and brain
stem centres are involved in the regulation of food intake
and energy balance but information on the relevant reg-
ulatory factors and their genes was scarce before the last
decade1. Insulin remained the only candidate for the key
role in body weight regulation for a long time. The dis-
covery of leptin is one of the most exciting findings of the
last decade. This cytokine-like peptide mainly expressed
by adipocytes is now believed to be a key regulator of fat
metabolism and energy intake. Leptin is the product of
human homologue of mouse ‘obese’ gene, whose
homozygous mutation caused hereditary obesity in mice
(monogenic).
The mechanisms participating in the effects of leptin
and other peptides on food intake and body weight
regulation are now becoming clearer. Certain areas of the
hypothalamus are rich in specific receptors binding
regulatory peptides and triggering central regulatory
mechanisms. Factors acting at the central nervous system
level include neuropeptide Y (NPY), corticotropin-releasing
hormone, proopiomelanocortin, a-melanocyte-stimulating
hormone, agouti-related protein, melanin-concentrating
hormone, cocaine- and amphetamine-regulated transcript
and other molecules. Interaction between them involving
complex neuronal mechanisms eventually influence the
behaviour and provide important links with neuroendo-
crine regulation of other vital functions of the organism2.
Studies in humans have failed to find leptin or
any other mutant gene to be the unique ‘obesity gene’.
Conversely, multifactorial patterns involving actions of
numerous polymorphic gene products now look more
likely. Evidence is accumulating that most of these genes
encoding central peptide factors as well as their receptors
(leptin receptors, melanocortin receptors, NPY receptors)
are polymorphic. Dominant inheritance of obesity con-
ferred by missense, nonsense and frameshift mutations in
the melanocortin 4 receptor (MC4R) gene has been
extensively reported in many populations including
French, English, German, American, Italian and Spanish
individuals2,7–10. It has been estimated that 1–6% of
extremely obese individuals harbour functionally relevant
MC4R mutations. More than 70 mutations of the MC4R,
57 non-synonymous, 5 nonsense and 10 frameshift
mutations, have been reported, many of them associated
with dominant inheritance of obesity7,9. Functional stu-
dies showed that many of the missense mutations also
lead to a loss-of-function of the MC4R. Meanwhile, other
mutations (i.e. Thr-11-Ser, Arg-18-Cys) and two poly-
morphisms (Val-103-Ile, Ile-251-Leu) did not modify the
function of the MC4R in vitro2.
NPY is released from the arcuate hypothalamic nucleus
in fasting or in hypoglycaemia situations, its secretion
being inhibited after food intake. The Leu7Pro poly-
morphism in the NPY gene appears to be implicated in
lipid metabolism regulation. Some works reported that
carriers of the Pro7 allele had higher NPY levels and also
body fatness11.
A number of peptides synthesised along the gastro-
intestinal tract also affect food intake. They include
ghrelin (orexigenic peptide mainly produced in the
stomach), cholecystokinin (produced in the small intes-
tine acting as a short-term satiety signal) and peptide
YY3-36 (produced in the colon and suppressing appetite
for up to 12 hours). Exploration of these signalling
pathways has started and it is becoming clear that poly-
morphism in relevant genes may have important func-
tional consequences. For the ghrelin receptor gene, two
SNPs were reported: Ala204Glu and Phe279Leu, which
selectively impair the constitutive activity of the receptor
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MC4R, MC3R, 
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Polygenic obesity
(113 candidate genes) 
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PPARG, PPARD,
ACDC, TNF alpha, IL6,
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in humans leading to short stature and obesity that
apparently develop during puberty12.
Moreover, the identification of relevant genes related to
food preferences has just started. A novel family of 40–80
human and rodent G protein-coupled receptors expres-
sed in taste receptor cells of tongue and palate epithelia
has been identified. Taste 2 receptors (T2Rs) have been
shown to function as bitter taste receptor and T1Rs as
putative receptor for sweet taste. There is no information
on polymorphism in the T1R family genes while some
SNPs in T2R have been reported13,14. Rapid progress has
been made in this field to elucidate the genetic mechan-
ism controlling formation of food preferences.
Genes encoding factors implicated in energy
expenditure
The adaptive thermogenesis in humans is closely related
to the active mobilisation of lipids from fat tissues and
demand special interest in relation to obesity. Central
neural pathways responsible for the food intake and
energy expenditure regulation are tightly interconnected.
The peripheral transmission of central commands to the
fat stores is mediated by the sympathetic nervous system.
b-adrenoceptor gene families (ADRB2, ADRB3, ADRB1)
are intensively studied candidate genes in the obesity
field for their participation in energy expenditure
regulation.
The b2-adrenergic receptor gene (ADRB2) encodes
a major lipolytic receptor protein in human fat cells.
Two common polymorphisms of the ADRB2 gene,
characterised by an amino acid replacement of arginine
by glycine in codon 16 (Arg16Gly) and glutamine by
glutamic acid in codon 27 (Gln27Glu), have been ex-
plored in several diseases such as hypertension and
obesity2,15–18. A relationship between the Arg16Gly
polymorphism and an altered function of the ADBR2 has
been reported leading to a decreased agonist sensitivity.
Meanwhile, the Gln27Glu variant was also found to be
linked to obesity in some populations. In men, the 27Glu
allele has been associated with increased BMI and sub-
cutaneous fat and with elevated leptin and triglycerides
levels, while in women, the 27Glu variant was reported
to be linked to increased BMI, body fat mass and waist-
to-hip ratio15–18. However, other studies in Caucasians
(Danish men, Austrian women and German subjects)
found no association between the Gln27Glu variant of
the ADRB2 gene and obesity2,6.
The b3-adrenergic receptor (ADRB3) protein plays
a role in adipocyte metabolism mediating the rate of
lipolysis in response to catecholamines and their
agonists have potential anti-diabetes and anti-obesity
properties2,19–22. A common polymorphism in this gene,
characterised by an amino acid replacement of trypto-
phan by arginine at position 64 (Trp64Arg), has been
identified and may be linked to lower lipolytic activity and
account for lipid accumulation in the adipose tissue. A
number of articles have reported the relationship between
the Trp64Arg variant of the ADRB3 and obesity-related
phenotypes. With regard to BMI, more than nine studies
have shown a statistically significant association between
BMI and the Trp64Arg polymorphism in a variety of
populations from 134 to 856 subjects. Besides, two meta-
analyses examining the effect of this mutation on BMI have
been published for Caucasian populations. One includes
2447 subjects and the significant BMI difference among
carriers and non-carriers of the mutation is 0.3022. The
second includes 7399 subjects but the results are negative
for the association22. This polymorphism has been asso-
ciated with abdominal/visceral fat obesity in several
populations such as Caucasians and Japanese subjects.
Similarly, several studies carried out among Mexican
American, Japanese and Caucasian women have shown
that carriers of the Arg allele had a higher BMI and
lower reduction in visceral fat after weight loss2,23. Some
authors, however, failed to reproduce the finding on b-
adrenoceptors gene variants and further confirmation is
required.
More recently, variants of the ADRB1 gene have been
studied in relation to obesity. The ADRB1 is also considered
a potential candidate gene for obesity because of its role in
catecholamine-induced energy homoeostasis. Stimulation
of ADRB1, a member of G-protein-coupled receptors,
mediates energy expenditure and lipolysis in adipose
tissue. In the C-terminal intracellular G-protein-coupling
domain of ADRB1, a polymorphism Arg389Gly has
been identified, with the Arg389 allele vs. the Gly389
allele displaying enhanced adenylate cyclase activity
in vitro24,25.
Whereas b-adrenoceptors participate in the regulation
of adaptive thermogenesis as a component of sympa-
thetic responses, uncoupling proteins (UCPs) are
involved in the modulation of heat-generating uncoupled
respiration at the mitochondrial level. They represent a
family of carrier proteins localised in the inner layer of
mitochondrial membranes22. There are different mem-
bers: UCP1, mostly expressed in brown adipose tissue,
has a role in thermogenesis, UCP2 is ubiquitously present
in any tissue and UCP3 is mainly expressed in the skeletal
muscle and brown adipose tissue. Their putative role as
‘uncoupling proteins’ has been intensively explored; like
UCP1, UCP2 mediates mitochondrial proton leak releas-
ing energy stores as heat and thereby affecting energy
metabolism efficiency22. The actual functions for UCP2
and UCP3 proteins are still under investigation. It has
been proposed that uncoupling proteins act as regulators
of energy metabolism, they being fatty acid transmem-
brane transporters in the mitochondria facilitating proton
exchange22.
Moreover, a number of human studies indicated the
relationship between UCP polymorphisms and exercise
efficiency, resting energy expenditure, substrate oxidation,
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energy metabolism, BMI, obesity risk, type 2 diabetes
risk, leptin, fat accumulation, body weight changes,
physical activity and so on2. These observations have led
to the consideration of UCP2 and UCP3 as candidate
genes for obesity, given their function in the regulation of
fuel metabolism.
Several UCP2 gene variants have been described: a G/A
mutation in the promoter region 2866G/A, a valine for
alanine substitution at amino acid 55 in exon 4 (Ala55Val)
and a 45 base pair insertion/deletion in the untranslated
region of exon 822,26,27. The association between these
polymorphisms of the UCP2 and various aspects of
obesity have been intensively studied. From the literature,
it seems that allele G in the promoter region of UCP2
increases obesity risk while it affords relative protection
for type 2 diabetes22. Meanwhile the Ala55Val poly-
morphism has shown to be associated with increased
exercise efficiency26. However, results concerning the
exon 8 insertion allele of the UCP2 gene have been
inconsistent. While no association with obesity was
observed in a number of studies conducted in several
populations, significant associations between the exon 8
insertion of the UCP2 gene and BMI or fat mass or pre-
sence of obesity were found with P values of 0.01, 0.001,
0.002 and 0.00522,27. A sixth study reported an association
of the exon 8 insertion allele with sleeping metabolic rate
(P5 0.007)26,27.
There are also several UCP3 gene variants. In linkage
studies, some of them have been associated to a higher
obesity risk22. Specifically, the255C/T polymorphism in the
promoter region of this gene has been associated with an
elevated BMI, an increased level of adiposity or a greater
waist-to-hip ratio28. However, other authors have not found
any relationship between this polymorphism and a higher
risk of obesity or changes in the metabolic rate28. Even some
studies have reported an inverse correlation with BMI and
the presence of 255C/T polymorphism28.
Genes encoding factors implicated in
adipogenesis
The last group of genes acting in connection with the
peripheral regulation of energy expenditure comprises
the transcription factors leading to adipogenesis and
adipocytes differentiation. The key actor is peroxisome
proliferator-activated receptor g, particularly the adipose-
specific isoform PPARG2. In a meta-analysis examining
the Pro12Ala polymorphism in 19 136 subjects, a positive
association with BMI was found22. In our study, the
frequency of the Ala allele, similar to other Caucasian
populations, was higher in obese subjects (allelic
frequency 0.13) than in controls (0.08), suggesting that
this polymorphism was associated with obesity29. There is
also information on the functional role of PPARG gene
variants. Some mutant proteins appear to have a reduced
activity22.
Monogenic obesity
The clinical features of human subjects with leptin (or
leptin receptor), proopiomelanocortin (POMC), MC4R
and proprotein convertase 1 (PC1) deficiency30 are often
associated with an obese phenotype.
Congenital human leptin deficiency has been identified
in subjects showing severe early-onset obesity (8 years
and 86 kg, or 2 years and 29 kg) with intense hyperphagia
and undetectable levels of serum leptin due to a frame-
shift mutation in the ob gene (deletion G133) in a
homozygosis, which resulted in a truncated protein not
secreted3. Children with leptin deficiency had also
profound abnormalities in T-cell number and function
consistent with high rates of infection and childhood
mortality from infections. Leptin therapy in these subjects
has a major effect on appetite with normalisation of
hyperphagia and reductions body weight. Leptin receptor-
deficient subjects were also found, with the phenotype
being similar to those with leptin deficiency. The birth
weight was normal, but a rapid weight gain was seen in
the first months of life, with severe hyperphagia and
aggressive behaviour when food was denied3,30. Basal
temperature and resting metabolic rate were normal and
they were normoglycemic with mildly elevated plasma
insulin as reported for leptin-deficient subjects. But
specifically, they also debut with mild growth
retardation and impaired basal and stimulated growth
hormone secretion3.
Homozygous and heterozygous subjects for mutations
in POMC have been found. In neonatal life these subjects
showed adrenocorticotropic hormone (ACTH) deficiency
(the POMC gene encoded ACTH and other peptides), the
children have red hair and pale skin due to the lack of
melanocyte-stimulating hormone (MSH) action at the
melanocortin-1 receptors in skin and hair follicles3. The
POMC deficiency is associated with hyperphagia and
early-onset obesity due to the lack of activation of the
melanocortin-4 receptor.
Since 1998 many groups have reported at least 70
mutations in MC4R mostly associated with severe early-
onset obesity7–10. Other clinical features of MC4R
mutation carriers are hyperphagia, accelerated linear
growth in children and marked increase in bone mineral
density. Probands with homozygous MC4R mutations
show more severe obesity than their heterozygous rela-
tives; thus, the mode of inheritance is codominant3. The
prevalence of pathogenic MC4R mutations varied, being
the highest in obese adults selected for severe childhood
obesity, suggesting that both factors, severe obesity and
early age of onset, may be markers of MC4R mutations. It
has been also shown that pathogenic MC4R mutations are
more prevalent in northern European populations than in
the Mediterranean or even Asian populations. The figures
for prevalence are always quite low, for example 68
obese patients with pathogenic MC4R mutations out of
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2000 or even one mutation in a sample of 3000 obese
patients in another published study7. Functional analyses
of these mutations allow us to classify them on the basis
of their effects on receptor signalling. For instance, some
authors demonstrated that mutations that caused intra-
cellular retention of the receptor in vitro were associated
with earlier age of onset and greater severity of obesity
than other mutations.
The extremely low prevalence of pathogenic MC4R
mutations in the general population underlies the fact that
the obesity epidemic is not an epidemic of new mutations.
Subject carriers of PC1 mutations mainly have severe
early-onset obesity, impaired prohormone processing
and hypocortisolaemia3. Another clinical feature is small
intestine dysfunction, which may result from an erroneous
maturation of propeptides within the PC1-secreting cells
along the gut3.
Syndromic forms of obesity
There are about 30 rare syndromes caused by discrete
genetics defects or chromosomal abnormalities with
obesity as a clinical feature in association with mental
retardation, dysmorphic features and organ-specific
abnormalities (i.e. pleiotropic syndromes)3,4. At least four
syndromes show severe hyperphagia and/or other signals
of hypothalamic dysfunction, indicating a plausible origin
at the level of the central nervous system. The most
frequent of these syndromes is Prader-Willi syndrome
(prevalence 1/25 000) characterised by obesity, hyper-
phagia, hypotonia, mental retardation, short stature and
hypogonadiotropic hypogonism. It is usually caused by
lack of the paternal segment 15q11.2-q12, either through
deletion of the paternal critical segment (75%) or through
loss of the entire paternal chromosome 15 with the pre-
sence of two maternal homologues in 22% of patients
(uniparental maternal disomy). One suggested mediator
of the obesity phenotype is ghrelin, the stomach-secreted
peptide that increased appetite by interacting with POMC/
CART (cocaine- and amphetamine-regulated transcript)
and NPY hypothalamic neurons whose levels are high in
Prader-Willi syndrome patients3,4.
The loss of the single-minded homologue 1 (SIM1)
gene in chromosome 6 has been associated with hyper-
phagia in syndromic obesity. This gene encoded a protein
which is a regulator of neurogenesis. In humans, deletion
or disruption of the SIM1 region results in either ‘Prader-
Willi-like’ phenotype or an early-onset obesity linked to
hyperphagia3,4.
Albright’s hereditary osteodystrophy is an autosomal
dominant disorder due to mutations in GNASI, which
encodes for a-subunit of the stimulatory G protein (Gs a).
Maternal transmission of GNASI mutations leads to
Albright’s hereditary osteodystrophy (obesity, short
stature, round facies, ectopic tissue ossification) plus
resistance to several hormones – such as parathyroid
hormone – which activate Gs in their target tissues,
while paternal transmission leads only to Albright’s
hereditary osteodystrophy phenotype (pseudopseudo-
hypoparathyroidism)3,4.
The origin of obesity is more complex in Bardet-Biedl
syndrome (prevalence of BBS, 1/100 000). It is an
autosomal recessive syndrome characterised by central
obesity (75%), polydactily, learning disabilities, rod–cone
dystrophy, hypogonadism and renal abnormalities. The
Bardet-Biedl syndrome is a genetically heterogenous
disorder that is known to map to at least eight loci, seven
of which have now been identified at the molecular level
(mutations in BBS1–BBS11 genes)3,4,31.
The molecular causes that underlie the aetiology of
syndromic obesity are far more complex than that for
monogenic obesity. Positional genetic strategies have led
to the recent identification of several causative mutations
responsible for these syndromes; however, in many cases
the defective gene product is a ubiquitously expressed
protein of unknown function.
Genetic and dietary influences at the present time
The interaction of functional gene polymorphisms with
environmental factors (gene–environment interactions)
plays a substantial role in obesity risk. Gene–environment
interaction implies that in combination the effect of
genotype and environment deviates from the additive
or multiplicative effects of the two factors. A simple
statistical approach to the analysis of gene–environment
interaction when dealing with a quantitative trait (e.g.
BMI) is to use the statistical test analysis of covariance,
with the quantitative trait being entered as the dependent
variable, genotype and environmental factors being
entered as main effects and with an interaction term
between the genotypic and environmental factors. If this
term is statistically significant, the implication is that there
is a greater or lesser additive effect and an interaction is
suggested. However, this outcome could be the result of
chance alone, which highlights the importance of con-
firmatory findings. If the P value for the interaction term is
not significant, the implication is that there is a lack of
interaction, but it could also simply reflect the lack of
power in the study to detect an effect2,5.
From a mechanistic viewpoint, interaction suggests that
at the molecular level the effect or byproducts of the
environmental insult modifies the molecular function of
the product of the gene under observation33–37. The
higher obesity risk will come from the co-existence of
both genetic and environmental influences at a high scale
for a given population. On one hand individuals inherited
a number of gene variants in key loci and on the other
they adopt a different position on the environmental
spectrum of risk by the lifestyle choices they make (e.g.
low-fat vs. high-fat diets, high vs. low levels of physical
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activity, etc.) Thus, while the environmental factors are
modifiable, the genetic factors are not32. Understanding
the gene–environment relationship is one of the big
challenges that is being faced.
Methodological aspects on the study of genetics
of obesity
A complementary strategy to the candidate gene
approach for the identification of obesity genes is the use
of genome-wide linkage scans. This strategy involves the
genotyping of families using polymorphic markers posi-
tioned across the whole genome followed by calculation
of the degree of linkage of the marker to a disease trait.
This approach does not rely on any pre-existing knowl-
edge of the genes related to the disease. For the study of
obesity, genome-wide linkage scans have been applied:
in families, representative of general population and also
in families chosen because they have an around obese
proband. This latter approach is very useful for linkage
analysis. In fact, the first genome scans for obesity located
a quantitative trait locus (QTL) for leptin levels and fat
mass at 2p21 in Mexican-Americans for the San Antonio
Family Heart Study. Subsequently, more than 204 quan-
titative trait loci for obesity-related phenotypes were
found on all but chromosome Y from more than 50
genome-wide scans reported since 19974,6. Most of the
genome-wide scans are based primarily on BMI mea-
surements. Several of these QTLs have been confirmed in
various studies, at least 38 QTLs showed evidence of
linkage in two studies6.
Nowadays, the availability of OMICs technology
represents a major event for studying the genetics of
obesity38–43. The different biomarkers at the transcript,
protein and metabolite level will hopefully develop into
indicative and predictive sets of molecules, their diag-
nostic power cannot be uncoupled from pre-determined
genetic disposition. Human genetic differences appear at
the level of SNPs, copy number polymorphisms and the
specific combinations of alleles (haplotypes). On top of
these levels of sequence variability, epigenetic phenom-
ena, such as DNA methylation, histone acetylation and
RNA interference, add to the complexity of individually
different gene regulation. Besides, the high throughput
offers the opportunity to genotype more than 10 000
samples a day and enables genomewide association
studies38–43. DNA hybridisation arrays represent a new
tool to study the association of several different poly-
morphisms with the development of obesity. Gene chips
containing 500 000 SNPs are already available allowing
the identification of possible mutations in known and
unknown genes related to obesity41. This technology
constitutes the appropriate tool for approaching the study
of those combinations of genes and mutations that are
implicated in the development of obesity in humans, as
well as for establishing how environmental factors affects
the onset of obesity in individuals with a specific genetic
background.
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